KHẢO SÁT TÌNH HÌNH SỬ DỤNG THUỐC ĐIỀU TRỊ RỐI LOẠN LIPID MÁU Ở BỆNH NHÂN ĐÁI THÁO ĐƯỜNG TYP 2 TẠI BỆNH VIỆN NỘI TIẾT TRUNG ƯƠNG

Abstract

We conducted this research to investigate the use of drugs for treatment of dyslipidaemias (RLLPM) as well as the effectiveness of controlling dyslipidaemias in people with type 2 diabetes who were inpatients at the National Hospital of Endocrinology. A cross-sectional study through retrospective medical records was carried out on 760 people with type 2 diabetes who used drugs for treatment of dyslipidaemias and was hospitalized from 1^st to 30^th in November 2023. The study’s results showed that the majority of the patients were between 40 and 75 years old (96,2%), and the proportion of females was higher than males (51,6% compared to 48,4%). In this research, the proportion of patients with normal physical condition was highest (40,9%) and the duration of patient’s diabetes was mainly over 10 years (44,3%). The majority of patients had liver enzymes within normal limits (57,1%) and had a slightly reduction in kidney function (50,7%). 50,1% of patients did not reach the LDL-C test result < 2,6 mmol/L threshold, 62,4% of patients had TG test result ≥ 1,7 mmol/L and 55,5% of patients did not reach the goal for HDL-C level. 100% of patients in research sample was at high and very high cardiovascular risk. The majority of patients were prescribed single regimens, accounting for 94,9%, of which single statin regimens accounted for 89,5%. At the time of admission, 93.7% of patients used moderate-intensity statins to strong-intensity statins and 6.3% of patients used fibrates or were not prescribed medication. 89,9% of patients did not have to change their regimens during inpatient treatment.